Exelixis, Inc. (NASDAQ:EXEL) Shares Acquired by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. grew its holdings in Exelixis, Inc. (NASDAQ:EXEL) by 5.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,470 shares of the biotechnology company’s stock after purchasing an additional 1,853 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Exelixis were worth $827,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Contravisory Investment Management Inc. acquired a new stake in shares of Exelixis in the fourth quarter valued at approximately $26,000. Denali Advisors LLC boosted its position in Exelixis by 7,995.2% during the third quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 1,679 shares during the last quarter. Fifth Third Bancorp boosted its position in Exelixis by 44.2% during the third quarter. Fifth Third Bancorp now owns 1,970 shares of the biotechnology company’s stock worth $43,000 after acquiring an additional 604 shares during the last quarter. Signaturefd LLC boosted its position in Exelixis by 17.1% during the third quarter. Signaturefd LLC now owns 4,577 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 668 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Exelixis during the third quarter worth approximately $100,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director David Edward Johnson purchased 190,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were purchased at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the purchase, the director now directly owns 1,100,730 shares of the company’s stock, valued at approximately $22,785,111. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director David Edward Johnson purchased 190,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were purchased at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the purchase, the director now directly owns 1,100,730 shares of the company’s stock, valued at approximately $22,785,111. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the sale, the director now directly owns 35,703 shares in the company, valued at approximately $857,229.03. The disclosure for this sale can be found here. Insiders own 2.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. William Blair restated an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. JMP Securities restated a “market outperform” rating and set a $27.00 target price on shares of Exelixis in a research report on Wednesday, April 10th. Barclays lowered shares of Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price on the stock. in a research report on Thursday, April 11th. Finally, Stifel Nicolaus lifted their price target on shares of Exelixis from $23.00 to $25.00 and gave the company a “hold” rating in a report on Friday, February 2nd. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Exelixis currently has a consensus rating of “Moderate Buy” and a consensus target price of $26.29.

Exelixis Trading Up 1.8 %

Shares of EXEL stock opened at $23.71 on Thursday. The company’s fifty day simple moving average is $22.67 and its 200-day simple moving average is $22.16. Exelixis, Inc. has a 52 week low of $18.08 and a 52 week high of $24.34. The company has a market cap of $6.99 billion, a PE ratio of 37.05, a P/E/G ratio of 0.61 and a beta of 0.54.

Exelixis (NASDAQ:EXEL) last issued its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 EPS for the quarter, beating analysts’ consensus estimates of $0.25 by $0.02. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. The business had revenue of $479.65 million for the quarter, compared to the consensus estimate of $481.23 million. Equities research analysts expect that Exelixis, Inc. will post 1.21 EPS for the current fiscal year.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.